AMRX vs MCK vs ANIP Stock Comparison

Amneal Pharmaceuticals, Mckesson and Ani Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
1 more company in this comparison (AMPH) Create a free account to keep reading and compare up to 10 companies.
MCK Mckesson Corp
$1,102.82 +12.7% 1M +30.3% 1Y
Market cap
$128.78B
P/E
27.4x
Revenue (TTM)
$418.79B
Div. yield
0.00%
Drug Distribution Healthcare
4 wins

Head to Head

11 decided of 12

Ani Pharmaceuticals leads on 6 of the 12 questions below (Ani Pharmaceuticals 6, Mckesson 4, Amneal Pharmaceuticals 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMRXMCKANIPLeader
Larger companyMarket capitalisation $7.10B $128.78B $1.50B MCK
Cheaper on earningsLower P/E, profitable companies only 53.2x 27.4x 12.8x ANIP
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.4x 22.8x 7.1x ANIP
Faster revenue growthRevenue growth, trailing twelve months +8.9% +8.2% +25.9% ANIP
More profitableNet margin, trailing twelve months 4.2% 1.1% 11.2% ANIP
Better return on capitalReturn on invested capital 14.3% 98.7% 13.4% MCK
Less leveragedLower net debt / EBITDA 4.3x 0.4x -0.5x ANIP
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +85.6% +30.3% -15.5% AMRX
Better 5-year returnAnnualised price return, 5 years +32.7%/yr +37.5%/yr +9.4%/yr MCK
Less volatileAnnualised volatility, 1 year 34.3% 31.4% 32.3% MCK
Higher overall scoreMean of the five percentile scores vs peers 69/100 58/100 84/100 ANIP

Percentile Scorecard

AMRXMCKANIP

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMRXMCKANIP
Valuation 90 #69 of 660 65 #10 of 27 96 #29 of 660
Growth 70 #189 of 619 56 #12 of 26 96 #23 of 619
Profitability 87 #80 of 595 56 #12 of 26 91 #54 of 595
Financial Health 11 #606 of 683 56 #12 of 26 44 #384 of 683
Shareholder Returns 89 #53 of 459 59 #8 of 18 93 #35 of 459
Overall 69 58 84
  • AMRX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • ANIP ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMRXMCKANIPSPY
1 month +13.1%+12.7%+1.8% -2.0%
3 months +17.8%+26.9%-6.7% -2.8%
6 months +79.2%+45.0%-8.4% +2.0%
Year to date +69.7%+34.4%-9.5% +10.6%
1 year +85.6%+30.3%-15.5% +12.2%
3 years +367.8%+143.0%+34.2% +68.1%
3 years, per year +67.3%+34.5%+10.3% +18.9%
5 years +310.4%+390.5%+56.8% +61.4%
5 years, per year +32.7%+37.5%+9.4% +10.1%
10 years —+671.0%+24.1% +248.5%
10 years, per year —+22.7%+2.2% +13.3%

Risk

MeasureAMRXMCKANIPSPY
Volatility, 1Y 34.3%31.4%32.3% 13.6%
Downside volatility, 1Y 30.7%27.2%31.8% 13.9%
Beta vs S&P 500, 1Y 0.67-0.180.27 1.00
Return / volatility, 1Y 2.490.97-0.48 0.90
Max drawdown, 5Y -75.4%-27.2%-54.6% -25.4%
From 52-week high -1.5%0.0%-17.0% -3.2%
52-week high $21.71$1,102.82$86.03 $779.14
52-week low $11.52$725.17$67.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMRXMCKANIP
P/E now vs peer median 53.8xmedian 17.0x 27.3xmedian 25.2x 13.0xmedian 17.0x
P/S now vs peer median 2.3xmedian 8.4x 0.3xmedian 0.4x 1.6xmedian 8.4x
EV/EBITDA now vs peer median 15.1xmedian 14.6x 17.4xmedian 14.5x 6.5xmedian 14.6x
P/FCF now vs peer median 193.9xmedian 19.0x 17.9xmedian 16.5x 8.3xmedian 19.0x
P/B now vs peer median 14.0xmedian 2.0x -32.2xmedian 2.7x 2.7xmedian 2.0x
PEG now vs peer median 0.65median 0.43 1.72median 1.72 0.12median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMRXMCKANIP
Revenue $3.20B $418.79B $1.04B
Gross profit $1.29B $15.37B $635.80M
Operating income $478.99M $6.69B $166.49M
Net income $175.49M $5.43B $116.84M
Free cash flow $38.42M $7.11B $205.32M
R&D $180.59M – $50.61M
EPS (diluted) $0.40 $40.27 $5.39
Cash & equivalents $157.40M $6.53B $420.76M
Total debt $3.12B $9.21B $297.68M
Shares (diluted) 335.73M 116.70M 21.68M
Enterprise value $6.33B $110.16B $119.09M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMRXMCKANIP
P/E 53.8x 27.3x 13.0x
P/FCF 193.9x 17.9x 8.3x
P/Operating cash flow 41.2x 17.0x 7.4x
P/S 2.3x 0.3x 1.6x
P/B 14.0x -32.2x 2.7x
P/Tangible book -7.3x -16.1x 8.4x
EV/EBITDA 15.1x 17.4x 6.5x
EV/EBIT 21.7x 19.4x 9.5x
EV/Revenue 3.3x 0.3x 1.5x
EV/FCF 271.0x 18.3x 7.7x
EV/Operating cash flow 57.6x 17.3x 6.9x
PEG (3Y EPS CAGR) 0.65 1.72 0.12

Growth

14 metrics
MetricAMRXMCKANIP
Revenue growth (1Y) 8.9% 8.2% 25.9%
Revenue CAGR (3Y) 10.2% 12.9% 32.3%
Gross profit growth (1Y) 19.2% 11.8% 25.8%
Gross profit CAGR (3Y) 15.0% 7.6% 30.7%
Operating income growth (1Y) 33.8% 27.3% 131.4%
Operating income CAGR (3Y) 28.4% 16.1% 58.2%
Net income growth (1Y) 271.2% 28.5% 188.0%
Net income CAGR (3Y) 53.6% 14.2% 105.9%
EPS growth (1Y) 2,085% 24.2% 191.5%
EPS CAGR (3Y) 83.1% 15.9% 106.2%
Operating cash flow growth (1Y) -44.9% 9.3% 34.3%
Operating cash flow CAGR (3Y) -1.1% 15.2% 48.6%
Free cash flow growth (1Y) -84.6% 11.8% 31.8%
Free cash flow CAGR (3Y) -35.0% 16.3% 50.6%

Profitability

14 metrics
MetricAMRXMCKANIP
Gross margin 40.2% 3.7% 61.1%
EBITDA margin 21.5% 1.8% 23.5%
Operating margin 15.0% 1.6% 16.0%
Pretax margin 6.9% 1.6% 15.2%
Net margin 4.2% 1.1% 11.2%
FCF margin 1.2% 1.7% 19.7%
Operating cash flow margin 5.7% 1.8% 22.0%
Return on equity 74.3% – 18.9%
Return on assets 4.6% 6.0% 7.6%
Return on invested capital 14.3% 98.7% 13.4%
Return on capital employed 14.1% 42.0% 13.8%
Asset turnover 0.7x 4.6x 0.7x
Cash conversion (OCF / net income) 1.0x 1.4x 2.0x
Stock comp / revenue 1.2% – 4.1%

Financial Health

11 metrics
MetricAMRXMCKANIP
Debt / assets 59.2% 10.0% 19.0%
Debt / equity 5.9x -2.3x 0.5x
Net debt / EBITDA 4.3x 0.4x -0.5x
Debt / FCF 81.2x 1.3x 1.4x
Liabilities / assets 89.9% 104.3% 59.4%
Equity / assets 10.1% -4.3% 40.6%
Interest coverage – 21.9x –
Current ratio 1.9x 0.9x 2.7x
Quick ratio 1.1x 0.5x 2.2x
Cash ratio 0.1x 0.1x 1.3x
Altman Z-score 1.96 5.83 2.61

Shareholder Returns

7 metrics
MetricAMRXMCKANIP
Dividend yield – 0.3% –
Net buyback yield 0.0% 5.2% 0.8%
Shareholder yield 0.0% 5.6% 0.8%
Payout ratio (earnings) – 7.4% –
Payout ratio (FCF) – 5.6% –
Dividend growth (1Y) – 10.5% –
Dividend CAGR (3Y) – 9.8% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMRXMCKANIP
Forward P/E 21.4xFY2026 22.8xFY2026 7.1xFY2026
EPS, next fiscal year $1.00FY2026 $48.34FY2026 $10.03FY2026
EPS growth, next FY +20.5%FY2026 +23.6%FY2026 +27.1%FY2026
EPS growth, the year after +26.0% +11.9% -3.9%
Revenue, next fiscal year $3.30BFY2026 $447.65BFY2026 $1.15BFY2026
Revenue growth, next FY +9.1%FY2026 +11.0%FY2026 +29.9%FY2026
Revenue growth, the year after +12.6% +1.5% +8.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMRXMCKANIP
Held by institutions 51.0% 89.1% 96.0%
Institutions holding 310 2,014 306
Change in shares held, QoQ +1.3% -0.7% -1.8%
Institutions buying 182 883 172
Institutions selling 86 793 88
Buyers to sellers 2.12 1.11 1.95

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMRXMCKANIP
AMRX 1.00 0.13 0.42
MCK 0.13 1.00 0.10
ANIP 0.42 0.10 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMRX, MCK and ANIP?

Mckesson (MCK) is the largest by market capitalisation: Amneal Pharmaceuticals (AMRX) $7.10B, Mckesson (MCK) $128.78B, Ani Pharmaceuticals (ANIP) $1.50B.

Which stock is cheaper, AMRX, MCK and ANIP?

Ani Pharmaceuticals (ANIP) trades on the lowest price-to-earnings ratio (Amneal Pharmaceuticals (AMRX) 53.2x, Mckesson (MCK) 27.4x, Ani Pharmaceuticals (ANIP) 12.8x). On next year's consensus earnings, Ani Pharmaceuticals (ANIP) is cheapest (Amneal Pharmaceuticals (AMRX) 21.4x, Mckesson (MCK) 22.8x, Ani Pharmaceuticals (ANIP) 7.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Ani Pharmaceuticals (ANIP) grew revenue fastest over the trailing twelve months: Amneal Pharmaceuticals (AMRX) +8.9%, Mckesson (MCK) +8.2%, Ani Pharmaceuticals (ANIP) +25.9%.

Which company is more profitable?

Ani Pharmaceuticals (ANIP) has the highest net margin (Amneal Pharmaceuticals (AMRX) 4.2%, Mckesson (MCK) 1.1%, Ani Pharmaceuticals (ANIP) 11.2%). On return on invested capital, Mckesson (MCK) leads (Amneal Pharmaceuticals (AMRX) 14.3%, Mckesson (MCK) 98.7%, Ani Pharmaceuticals (ANIP) 13.4%).

Which stock has performed better?

Over the past year Amneal Pharmaceuticals (AMRX) returned the most: Amneal Pharmaceuticals (AMRX) +85.6%, Mckesson (MCK) +30.3%, Ani Pharmaceuticals (ANIP) -15.5%. Over five years, Mckesson (MCK) compounded fastest (Amneal Pharmaceuticals (AMRX) +32.7%/yr, Mckesson (MCK) +37.5%/yr, Ani Pharmaceuticals (ANIP) +9.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Amneal Pharmaceuticals (AMRX) 0.00%, Mckesson (MCK) 0.00%, Ani Pharmaceuticals (ANIP) 0.00%. Amneal Pharmaceuticals (AMRX) and Ani Pharmaceuticals (ANIP) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Amneal Pharmaceuticals (AMRX) 34.3%, Mckesson (MCK) 31.4%, Ani Pharmaceuticals (ANIP) 32.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMRX, MCK and ANIP?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Ani Pharmaceuticals (ANIP) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.